175 related articles for article (PubMed ID: 20092387)
1. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
[TBL] [Abstract][Full Text] [Related]
3. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
6. Can we decrease breakthrough bleeding in patients with endometriosis on norethindrone acetate?
Muneyyirci-Delale O; Jalou S; Rahman M; Nacharaju V
Int J Fertil Womens Med; 2003; 48(1):32-6. PubMed ID: 12643518
[TBL] [Abstract][Full Text] [Related]
7. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
[TBL] [Abstract][Full Text] [Related]
9. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
10. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
Mettler L
Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
[TBL] [Abstract][Full Text] [Related]
11. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
12. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic management of endometriosis.
Saltiel E; Garabedian-Ruffalo SM
Clin Pharm; 1991 Jul; 10(7):518-31. PubMed ID: 1830521
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of domestic luteinizing hormone-releasing hormone analogue and low-dose norethindrone "add-back" therapy in the treatment of endometriosis].
Zhang S; Ye G; Chen H
Zhonghua Fu Chan Ke Za Zhi; 2000 Aug; 35(8):482-5. PubMed ID: 11776204
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
17. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
18. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL
Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253
[TBL] [Abstract][Full Text] [Related]
19. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey ES
Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
